Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
Public ClinicalTrials.gov record NCT00913393. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
Study identification
- NCT ID
- NCT00913393
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- May 31, 2010
- Completion
- May 31, 2010
- Last update posted
- Feb 21, 2019
2009 – 2010
United States locations
- U.S. sites
- 28
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tempe | Arizona | — | — |
| Not listed | Buena Park | California | — | — |
| Not listed | Lakewood | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Evergreen Park | Illinois | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Kenner | Louisiana | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | Saint Clair Shores | Michigan | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Berlin | New Jersey | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | Flushing | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00913393, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2019 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00913393 live on ClinicalTrials.gov.